ArticleBone marrow transplantation2002
Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease.
Article in Bone marrow transplantation, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00286325 (Rituximab in the Treatment of Patients With Bullous Pemphigoid), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rituximab in the Treatment of Patients With Bullous Pemphigoid
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.Frontiers in immunology · 2022Pooled it
- Refractory ulcerations treated with timolol due to bullous pemphigoid in the setting of chronic cutaneous graft-versus-host disease.JAAD case reports · 2025Article
- Bullous Pemphigoid as a Manifestation of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Report of a Novel Case.Journal of clinical medicine · 2025Review
- Bullous Diseases in Children: A Review of Clinical Features and Treatment Options.Paediatric drugs · 2019Review
- Rituximab for autoimmune blistering diseases: recent studies, new insights.Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia · 2012Article
- Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease.Journal of the American Academy of Dermatology · 2012Article
- Oral lesions and lymphoproliferative disorders.Journal of oncology · 2010Article
- Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007.Therapeutics and clinical risk management · 2009Article
- Treatment strategies in mucous membrane pemphigoid.Therapeutics and clinical risk management · 2008Article
- Rituximab in treatment-resistant autoimmune blistering skin disorders.Clinical reviews in allergy & immunology · 2008Review
- Cicatricial pemphigoid of the oropharynx after allogeneic stem cell transplantation for relapsed follicular lymphoma.International journal of hematology · 2005Article
- Successful anti-CD20 antibody treatment of pemphigus foliaceus after unrelated cord blood transplantation.Bone marrow transplantation · 2005Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
In this case report we describe a novel treatment with two chimeric monoclonal antibodies (MoAb) targeting the autoimmune B cell clone responsible for bullous pemphigoid (BP) as a manifestation of steroid refractory chronic graft-versus-host disease (GVHD) that developed after unrelated cord blood transplantation. Monitoring the BP-specific circulating antibodies and CD25-expressing activated T lymphocyte subset led us to combine anti-CD20 (Rituximab) mediated B cell ablation with anti-CD25 (Daclizumab) therapy to block CD4(+) T cell help. Complete clinical and serologic response was achieved within 4 weeks of initiation of therapy allowing global immunosuppression to be dramatically reduced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.